Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 10/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319190 | 0.82 | GPR35 (0.57) | GPR35PTPN1PKMNPSR1RXFP1 | |
| SCHEMBL6803577 | 0.82 | GPR35 (0.47) | GPR35PTPN1PKMHPGDALDH1A1 | |
| SCHEMBL2727696 | 0.82 | GPR35 (0.66) | GPR35PTPN1PKMNPSR1RXFP1 | |
| SCHEMBL16172596 | 0.80 | GPR35 (0.46) | GPR35PTPN1NPSR1RXFP1HPGD | |
| SCHEMBL25195925 | 0.78 | GPR35 (0.53) | GPR35PKMNPSR1RXFP1TSHR | |
| SCHEMBL4582179 | 0.78 | GPR35 (0.54) | GPR35PTPN1TSHRHPGDALDH1A1 | |
| SCHEMBL1973056 | 0.77 | MAPT (0.50) | GPR35RXFP1TSHRHPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL8935194 | 0.76 | GPR35 (0.52) | GPR35PTPN1TSHRHPGDALDH1A1 | |
| SCHEMBL6927622 | 0.75 | GPR35 (0.50) | GPR35PTPN1PKMNPSR1RXFP1 | |
| SCHEMBL16057089 | 0.75 | GPR35 (0.50) | GPR35PTPN1PKMNPSR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884643-B2 | Substituted thiophenecarboxamides and analogues as antibacterials agents | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-30 | — | — | US | claimed |
| EP-3818050-B1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | BAYER AG (DE) | 2023-05-31 | — | — | EP | claimed |
| US-20230159506-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-25 | — | — | US | claimed |
| EP-3818050-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | Bayer Aktiengesellschaft (DE) | 2021-05-12 | — | — | EP | claimed |
| CN-112638893-A | Substituted thiophenecarboxamides and analogs as antibacterial agents | 拜耳公司 | 2021-04-09 | — | — | CN | claimed |
| WO-2020007905-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-09 | — | — | WO | claimed |
| WO-2008109786-A2 | REGIO-SELECTIVE ULLMANN SYNTHESIS OF 4-BROMO-3-METHYL-5-PROPOXY-THIOPHENE-2-CARBOXYLIC ACID | SANOFI-AVENTIS (FR) | 2008-09-12 | — | — | WO | claimed |
| US-12516037-B2 | Substituted thiophenecarboxamides and analogues as antibacterials agents | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-06 | — | — | US | disclosed |
| US-12509437-B2 | Substituted thiophene carboxamides and derivatives thereof as microbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-30 | — | — | US | disclosed |
| CN-115087650-B | Substituted thiophenecarboxamides and derivatives thereof as microbiocides | 拜耳公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20240360098-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-10-31 | — | — | US | disclosed |
| EP-4077303-B1 | SUBSTITUTED THIOPHENE CARBOXAMIDES AND DERIVATIVES THEREOF AS MICROBIOCIDES | BAYER AG (DE) | 2024-05-29 | — | — | EP | disclosed |
| US-11952359-B2 | Substituted thiophenecarboxamides and analogues as antibacterials agents | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-09 | — | — | US | disclosed |
| US-9012655-B2 | Antimicrobial/adjuvant compounds and methods | Denouamed, Inc. (CA) | 2015-04-21 | — | — | US | disclosed |
| US-9012655-B2 | Antimicrobial/adjuvant compounds and methods | Denouamed, Inc. (CA) | 2015-04-21 | — | — | US | disclosed |
| US-20140309266-A1 | ANTIMICROBIAL/ADJUVANT COMPOUNDS AND METHODS | DENOVAMED INC. (CA) | 2014-10-16 | — | — | US | disclosed |
| US-20140309266-A1 | ANTIMICROBIAL/ADJUVANT COMPOUNDS AND METHODS | DENOVAMED INC. (CA) | 2014-10-16 | — | — | US | disclosed |
| WO-2008109786-A3 | REGIO-SELECTIVE ULLMANN SYNTHESIS OF 4-BROMO-3-METHYL-5-PROPOXY-THIOPHENE-2-CARBOXYLIC ACID | SANOFI AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008109786-A2 | REGIO-SELECTIVE ULLMANN SYNTHESIS OF 4-BROMO-3-METHYL-5-PROPOXY-THIOPHENE-2-CARBOXYLIC ACID | SANOFI-AVENTIS (FR) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008109786-A2 | REGIO-SELECTIVE ULLMANN SYNTHESIS OF 4-BROMO-3-METHYL-5-PROPOXY-THIOPHENE-2-CARBOXYLIC ACID | SANOFI-AVENTIS (FR) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309266-A1 | ANTIMICROBIAL/ADJUVANT COMPOUNDS AND METHODS | S100A11, IFNG, MYD88 | GPR35 2787/4885PTPN1 2079/4885PKM 3776/4885 |
| US-12509437-B2 | Substituted thiophene carboxamides and derivatives thereof as microbicides | CBR1, CBR3, CCR2 | GPR35 3093/4885PTPN1 146/4885PKM 3177/4885 |
| US-11884643-B2 | Substituted thiophenecarboxamides and analogues as antibacterials agents | XDH, TST, BLVRB | GPR35 3838/4885PTPN1 1169/4885PKM 3637/4885 |
| US-20240360098-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | TST, TBK1, PGLS | GPR35 3382/4885PTPN1 904/4885PKM 3744/4885 |
| US-20230159506-A1 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | XDH, TST, BLVRB | GPR35 3838/4885PTPN1 1169/4885PKM 3637/4885 |
| US-11952359-B2 | Substituted thiophenecarboxamides and analogues as antibacterials agents | TST, XDH, PGLS | GPR35 3109/4885PTPN1 840/4885PKM 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.